Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 33%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is expected to see potential growth and profitability in the future due to their strong revenue and upcoming product launches, such as the Mobi Tubeless pump and expansion into the pharmacy channel. However, there are potential risks, such as competition and slow adoption, that may hinder this growth. With analysts setting a price target of $27, Tandem Diabetes Care has the potential for larger recurring revenue in the future, but may see a decrease in revenue in the short term due to their focus on the pharmacy channel.

Bears say

Tandem Diabetes Care is facing headwinds such as supplier shortages causing a slowdown in revenue growth, and the transition to a pay-as-you-go model and pharmacy channel is expected to negatively impact near-term revenue. While this shift may drive long-term growth potential, Tandem Diabetes faces competition in the AID market and will need to execute on new product introductions to maintain market share and drive revenue growth. Overall, the potential for sustained revenue growth and margin expansion is uncertain, leading to a negative outlook on the company's stock.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 33% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.